Satellos Bioscience Inc. focuses on developing treatments for degenerative muscle diseases using its proprietary MyoReGenX platform. The company shows strong liquidity with a current ratio of 10.70 and no debt, indicating financial stability. However, it faces concerns with negative ROE and ROA, suggesting inefficiencies in generating profits. The market cap of $193.49M and a price of $9.23 may indicate undervaluation, but the lack of profitability raises questions about long-term growth potential.
Loading financial metrics...
Company posted a loss of $-23.7M over the last year, representing Infinity% of revenue.
Operating cash flow has been negative for 3 consecutive quarters, burning $24.1M over the last year.
Debt-free balance sheet with a solid cash position, providing significant financial flexibility.
Excellent liquidity with current ratio of 10.7x ensures operational stability.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Biotechnology companies of a similar size
Based on 2025-Q3 (September 30, 2025)